Apellis Pharmaceuticals, Inc. 13D

Biogen Inc. completed its tender offer and Section 251(h) merger to acquire all outstanding shares of Apellis Pharmaceuticals, Inc., converting it into a wholly owned subsidiary and filing this Schedule 13D/A as a final exit filing.

Biogen Inc. filed Amendment No. 1 to its Schedule 13D on May 14, 2026 as a final, exit filing in connection with its completed acquisition of Apellis Pharmaceuticals, Inc., following a tender offer at $41.00 per share plus a contingent value right of up to $4.00 per share and the subsequent Section 251(h) merger that converted Apellis into a wholly owned subsidiary of Biogen; as a result, the prior tender and support agreement terminated and Biogen now effectively controls 100% of Apellis with no remaining public float.

Filing Facts

CIK

1492422

Ticker

APLS

Form

13D

Source Type

fda

Accession

0000950157-26-000611

Alert Tier

8